Core Viewpoint - The eleventh batch of national organized drug procurement has commenced, involving over 400 companies and covering 55 drug varieties, with a focus on quality control and fair competition in pricing [1] Group 1: Procurement Details - The procurement process started at 7:30 AM in Qingpu District, Shanghai, with public disclosure of application information at 10:30 AM [1] - The procurement includes significant products such as cefoperazone injection and dapagliflozin oral sustained-release formulation, projected to achieve sales in the billions for 2024 [1] - Major pharmaceutical companies like Heng Rui Medicine, Qilu Pharmaceutical, and AstraZeneca are participating with multiple products [1] Group 2: Procurement Rules - The new procurement rules emphasize "stabilizing clinical use, ensuring quality, preventing internal competition, and avoiding collusion" [1] - For the first time, medical institutions are allowed to report quantities based on brand names, enhancing the focus on quality control [1] - Each participating company must commit to pricing no lower than their costs, with lower-priced bids requiring a justification for their pricing to promote healthy market competition [1]

Policy Developments - The National Health Commission emphasizes the construction of a fertility-friendly society, promoting supportive policies for childbirth, elderly care, and the gradual delay of retirement age to optimize population structure [1] Drug Approval - East China Pharmaceutical's subsidiary received approval for the drug Mevanertinib, a new treatment for advanced or metastatic non-small cell lung cancer, with a direct R&D investment of approximately 306 million yuan [2] - Hengrui Medicine's subsidiary received approval for a fixed-dose combination of three oral diabetes medications, marking the first of its kind in China [3] Financial Reports - Shuanglu Pharmaceutical reported a 143.28% year-on-year increase in net profit for Q3, driven by gains from financial assets [4] - Huitai Medical announced a 18.02% increase in net profit for the first three quarters, with Q3 revenue up 24.77% [5] Capital Market - WuXi AppTec plans to sell 100% equity of two subsidiaries for 2.8 billion yuan to focus on its CRDMO business model, enhancing its global capabilities [7] Industry Events - The Ministry of Industry and Information Technology conducted a survey on the traditional Chinese medicine industry, aiming to promote modernization and quality improvement [8] - Shanghai's biopharmaceutical industry is projected to exceed 1 trillion yuan, marking it as the fifth trillion-level industry in the city [9] - The Jiangxi Pharmaceutical Development Conference resulted in the signing of 16 key pharmaceutical projects across various sectors [10] Public Sentiment - Beilu Pharmaceutical announced that a major shareholder plans to reduce its stake by up to 1.78% to improve asset liquidity [11]

Market Performance - The market experienced a rebound last week, with the CSI Xinhua National Brand Index rising by 4.14% to 2037.67 points [1][2] - The Shanghai Composite Index increased by 2.88%, the Shenzhen Component Index by 4.73%, the ChiNext Index by 8.05%, and the CSI 300 Index by 3.24% [2] Strong Stock Performances - Notable strong performers included: - Zhongji Xuchuang (up 32.23%) - Shiyuan Technology (up 14.54%) - Sunshine Power (up 14.37%) [2] - Other stocks with significant gains included: - Anji Technology and Wowo Bio (both up over 10%) - SMIC and Zhaoyi Innovation (both up over 9%) [2] Year-to-Date Stock Performance - Since the beginning of the second half of the year, Zhongji Xuchuang has surged by 239.03%, leading the gains [3] - Sunshine Power has increased by 145.06%, while other stocks like Lanke Technology and Yiwei Lithium Energy have risen over 70% [3] Market Outlook - According to Fangzheng Fubang Fund, liquidity remains a crucial driver for market development, and future capital inflow will significantly impact market trends [4] - The fund suggests focusing on sectors with solid fundamentals and reasonable valuations, rather than chasing high-performing stocks with poor earnings [4] - Long-term investment opportunities may lie in technology companies with real technological barriers that align with national strategies [4] - Kangmand Capital anticipates a volatile market in the short term due to uncertainties, but the core logic for an upward trend remains unchanged [4] - Xingshi Investment notes that positive incremental information could stabilize market expectations and emotions, with a potential shift in economic momentum towards technology and consumption [4]

Group 1 - The core point of the article is the performance and changes in the top holdings of the Yinhua CSI Innovation Drug Industry ETF, which reported a net value growth rate of 24.54% over the past year [1] - The fund has added new top holdings including Kanglong Chemical and Baile Tianheng, while increasing its stake in WuXi AppTec by 64.87 million shares, making it the largest holding [1] - The fund has exited from its previous top holdings, including Tigermed and Tonghua Golden Horse [1] Group 2 - The detailed data shows the number of shares held and market value for each of the top holdings, with WuXi AppTec holding 15.52 million shares valued at 1.74 billion and Kanglong Chemical holding 8.56 million shares valued at 306 million [1] - Other significant holdings include Hengrui Medicine, Changchun High-tech, and Kelun Pharmaceutical, with respective increases in shareholding [1] - The report indicates a strategic shift in the fund's portfolio, reflecting a focus on companies with strong growth potential in the pharmaceutical sector [1]

每经记者｜林姿辰 每经编辑｜魏文艺 "全世界也找不出第二家公司，像恒瑞医药有这么完整的布局⋯⋯那么，出海的标准是什么？" 10月26日，恒瑞医药全球研发总裁张连山在第十届医药创新与投资大会上向包括《每日经济新闻》记者 在内的媒体表示，创新药出海的首要前提是认清产品的差异化价值，并非只有First-in-Class（同类首 创）才能打开海外市场，如果产品能跻身前三或前五梯队，具备足够的临床差异化优势，同样能获得海 外企业的认可，由此促成的BD（商务拓展）合作，是恒瑞医药出海的第一步。 第二步，是推动优质产品的海外自主开发。张连山表示，对于部分具备明确临床价值，但尚未进入海外 药企重点布局范围的新药，恒瑞医药会依托在中国已积累的临床数据，以相对较低的研发投入，推动其 在海外的临床试验与上市申报。 "这是国际化的两步，第一步借船出海，第二步还是要回归到造船出海，为创新产品的价值实现画了一 个句号，这是目前公司出海的大概策略。"张连山表示，自己不会给出突破性进展的时间表，"因为做药 是Science（科学），有很多不确定性，今天好了，明天可能死掉了，很多产品在三期（临床试验）失 败的可能性比较小，但还是有的。我们还是 ...

Investment Rating - The report maintains an "Overweight" investment rating for the pharmaceutical and biotechnology industry [1]. Core Insights - The report highlights that the 2025 ESMO conference showcased significant advancements from Chinese innovative drug companies, marking a shift from being followers to leaders in the global market [19][22]. - The A-share pharmaceutical index has shown a year-to-date increase of 19.54%, with a weekly increase of 0.58%, while the Hang Seng Biotechnology Index has surged by 81.15% year-to-date [9]. - Key sub-sectors showing positive performance include medical services (+3.94%), pharmaceutical commerce (+2.27%), and medical devices (+0.89%), while chemical pharmaceuticals and traditional Chinese medicine experienced declines [9]. Summary by Sections Industry Trends - The report notes that the Chinese pharmaceutical sector is entering a harvest period, with a significant increase in the number and quality of research presented at the ESMO conference [16][19]. - The report emphasizes the successful approval of innovative drugs, such as Boehringer Ingelheim's treatment for pulmonary fibrosis and Novartis' drug for polymyalgia rheumatica, which have achieved significant clinical milestones [4]. Research and Development Progress - The report details several groundbreaking studies that have the potential to change existing treatment paradigms, including studies on innovative drugs and ADCs (antibody-drug conjugates) [4][22]. - Specific companies are highlighted for their promising research pipelines, including Innovent Biologics, Rongchang Biologics, and others, which have made significant contributions to the field [12][22]. Market Performance - The report provides a detailed analysis of stock performance within the pharmaceutical sector, noting that certain stocks, such as Teva Pharmaceutical and ST Rong Control, have seen significant weekly gains [9][11]. - The report suggests a ranking of favored sub-sectors for investment, with innovative drugs, research services, and CXO services at the top of the list [10][12]. Recommendations - The report recommends specific companies for investment based on their performance and potential, including Hengrui Medicine, WuXi AppTec, and others across various sub-sectors [11][12].

Investment Rating - The report maintains an investment rating of "Outperform" with a rating of A [5] Core Insights - The report highlights the significant performance of domestic new drugs showcased at the ESMO 2025 conference, with several companies presenting excellent clinical data [3][21] - The report emphasizes the importance of academic conferences as key catalysts for the innovative drug sector, particularly mentioning ESMO, ASCO, and WCLC as critical events for Chinese pharmaceutical companies [20] Weekly New Drug Market Review - From October 20 to October 26, 2025, the top five gainers in the new drug sector were: - 欧康维视 (+8.87%) - 君圣泰 (+8.21%) - 诺思兰德 (+7.07%) - 友芝友 (+4.42%) - 海创药业 (+3.73%) - The top five losers were: - 康宁杰瑞 (-17.72%) - 北海康成 (-14.42%) - 创胜集团 (-14.29%) - 宜明昂科 (-13.40%) - 来凯医药 (-12.40%) [16][17] Recommended Focus Stocks - The report suggests focusing on several stocks with potential catalysts, including: 1. Products with high overseas volume certainty after MNC certification: - PD-1 upgraded product: 三生制药 - GLP-1 asset: 联邦制药 - ADC assets: 科伦博泰, 百利天恒 2. Potential heavyweights for overseas MNC authorization: - PD-1 upgraded products: 康方生物, 信达生物 - Breakthroughs in autoimmune fields: 益方生物, 中国抗体 - Innovative target ADC: 复宏汉霖, 石药集团 3. Stocks likely to benefit from medical insurance negotiations and commercial insurance innovative drug directories: - Beneficiaries of medical insurance directory: 恒瑞医药, 康诺亚, 迈威生物, 智翔金泰, 海创药业 - Beneficiaries of commercial insurance innovative drug directory: 药明巨诺, 科济药业 [2][20] New Drug Approval and Acceptance - This week, four new drug or new indication applications were approved, and five new drug or new indication applications were accepted in the domestic market [9] - A total of 46 new drug clinical applications were approved, and 31 new drug clinical applications were accepted [10] Key Domestic Market Events - 信达生物 announced a global strategic partnership with Takeda to accelerate the development of new generation tumor immunotherapy and antibody-drug conjugate therapies [11] - 康宁杰瑞 and 石药集团 announced that their HER2 bispecific antibody-drug conjugate JSKN003 received breakthrough therapy designation from the CDE [11] - 和黄医药 presented clinical data for HMPL-A251 at the AACR-NCI-EORTC conference [11] Key Overseas Market Events - 罗氏 received FDA approval for Gazyva/Gazyvaro for the treatment of active lupus nephritis in adult patients [12] - Electra Therapeutics announced that its therapy ELA026 received breakthrough therapy designation from the FDA and PRIME qualification from the EMA [12] - 安斯泰来 announced that the FDA accepted its supplemental biologics license application for the antibody-drug conjugate Padcev in combination with Keytruda [12]

Investment Rating - The report maintains a positive outlook on the pharmaceutical sector, indicating an "Overweight" rating for the industry, suggesting it is expected to outperform the overall market [32]. Core Insights - The report highlights that the Shenwan Pharmaceutical and Biological Index increased by 0.6% this week, while the Shanghai Composite Index rose by 2.9% and the Wind All A (excluding financials and petrochemicals) increased by 3.7% [4][6]. - The pharmaceutical sector's overall valuation stands at 30.4 times earnings, ranking 9th among 31 Shenwan primary industries [4][8]. - Significant collaborations and clinical trial results were reported, including a $11.4 billion global strategic partnership between Innovent Biologics and Takeda Pharmaceutical, which includes a $1.2 billion upfront payment [5][13]. - Key clinical trial results presented at the 2025 ESMO conference showed promising outcomes for several drugs, indicating advancements in treatment efficacy for various cancers [14][18][19]. Market Performance - The report details the performance of various sub-sectors within the pharmaceutical industry, with notable increases in medical devices (+0.2%), medical consumables (+1.7%), and medical research outsourcing (+5.5%), while traditional Chinese medicine and other biological products saw declines [4][8]. - The report also notes that 99 A-share pharmaceutical companies released their Q3 2025 earnings, with a total revenue of 94.15 billion yuan, reflecting a 1.3% year-on-year increase [20][22]. Key Events - The report mentions that Bairui Tianheng has passed the Hong Kong Stock Exchange hearing and is in the process of listing its H-shares [12]. - The report emphasizes the importance of the 2025 ESMO conference, where several companies presented significant clinical data, enhancing their market visibility and potential investment attractiveness [14][17][18]. Company Recommendations - The report recommends focusing on innovative drug sectors and companies with improving performance in medical devices and upstream sectors, including companies like Hengrui Medicine, Changchun High-tech, and Mindray Medical [5][20].

Group 1 - The core viewpoint of the article highlights the performance of the Ping An CSI A50 ETF, which reported a net value growth rate of 16.91% over the past year [1] - The fund's top ten holdings saw the addition of Luxshare Precision, while Citic Securities exited the top ten [1] - The largest holding in the fund is CATL, accounting for 11.08% of the total holdings, with a significant reduction in positions for several other stocks [1] Group 2 - The report provides detailed changes in the fund's top holdings, including a 22.68% reduction in CATL shares, a 22.5% reduction in Kweichow Moutai, and a 22.55% reduction in Ping An Insurance [1] - Luxshare Precision was newly added to the top ten holdings with 3.21 million shares valued at 208 million yuan [1] - The fund's recent performance includes a 0.96% change over the last five days, with a net inflow of 14.639 million yuan [3]

Core Viewpoint - Heng Rui Medicine's subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the launch of HR20031 tablets, which are indicated for improving blood sugar control in adults with type 2 diabetes who have inadequate control with metformin [1] Company Summary - Heng Rui Medicine (600276) announced the approval of its HR20031 tablets, which combine empagliflozin, linagliptin, and metformin [1] - The approved indication for HR20031 is to be used in conjunction with diet control and exercise for adult patients with type 2 diabetes [1] Industry Summary - The approval of HR20031 tablets reflects ongoing advancements in diabetes treatment options within the pharmaceutical industry [1] - The product aims to address the needs of patients with type 2 diabetes who struggle with blood sugar control despite existing treatments [1]